Your browser doesn't support javascript.
loading
Efficacy of AS04-Adjuvanted Vaccine Against Human Papillomavirus (HPV) Types 16 and 18 in Clearing Incident HPV Infections: Pooled Analysis of Data From the Costa Rica Vaccine Trial and the PATRICIA Study.
Tota, Joseph E; Struyf, Frank; Hildesheim, Allan; Gonzalez, Paula; Ryser, Martin; Herrero, Rolando; Schussler, John; Karkada, Naveen; Rodriguez, Ana Cecilia; Folschweiller, Nicolas; Porras, Carolina; Schiffman, Mark; Schiller, John T; Quint, Wim; Kreimer, Aimée R; Lehtinen, Matti; Wheeler, Cosette M; Sampson, Joshua N.
Affiliation
  • Tota JE; Divison of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA.
  • Struyf F; Janssen Research & Development, Beerse, Belgium.
  • Hildesheim A; Divison of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA.
  • Gonzalez P; Agencia Costarricense de Investigaciones Biomédicas, Fundación INCIENSA, Guanacaste, Costa Rica.
  • Ryser M; GlaxoSmithKline Biologicals, Wavre, Belgium.
  • Herrero R; Agencia Costarricense de Investigaciones Biomédicas, Fundación INCIENSA, Guanacaste, Costa Rica.
  • Schussler J; Section of Early Detection and Prevention, International Agency for Research on Cancer, Lyon, France.
  • Karkada N; Information Management Services, Rockville, Maryland, USA.
  • Rodriguez AC; GlaxoSmithKline Biologicals, Wavre, Belgium.
  • Folschweiller N; Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, San José, Costa Rica.
  • Porras C; GlaxoSmithKline Biologicals, Wavre, Belgium.
  • Schiffman M; Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, San José, Costa Rica.
  • Schiller JT; Divison of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA.
  • Quint W; Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
  • Kreimer AR; DDL Diagnostic Laboratory, Rijswijk, the Netherlands.
  • Lehtinen M; Divison of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA.
  • Wheeler CM; University of Tampere, School of Public Health, Tampere, Finland.
  • Sampson JN; Department of Pathology and Obstetrics and Gynecology, University of New Mexico Cancer Center, Albuquerque, New Mexico, USA.
J Infect Dis ; 223(9): 1576-1581, 2021 05 20.
Article in En | MEDLINE | ID: mdl-32887990
ABSTRACT
Clinical trial data and real-world evidence suggest that the AS04-adjuvanted vaccine targeting human papillomavirus types 16 and 18 (AS04-HPV-16/18) vaccine provides nearly 90% protection against cervical intraepithelial neoplasia grade 3 or higher irrespective of type, among women vaccinated before sexual debut. This high efficacy is not fully explained by cross-protection. Although AS04-HPV-16/18 vaccination does not affect clearance of prevalent infections, it may accelerate clearance of newly acquired infections. We pooled data from 2 large-scale randomized controlled trials to evaluate efficacy of the AS04-HPV-16/18 vaccine against clearance of nontargeted incident infections. Results of our analysis do not suggest an effect in expediting clearance of incident infections.
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Uterine Cervical Neoplasms / Papillomavirus Infections / Papillomavirus Vaccines Type of study: Clinical_trials Limits: Female / Humans Country/Region as subject: America central / Costa rica Language: En Journal: J Infect Dis Year: 2021 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Uterine Cervical Neoplasms / Papillomavirus Infections / Papillomavirus Vaccines Type of study: Clinical_trials Limits: Female / Humans Country/Region as subject: America central / Costa rica Language: En Journal: J Infect Dis Year: 2021 Type: Article Affiliation country: United States